- Conditions
- Schizophrenia
- Interventions
- Olanzapine, Aripiprazole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Garden Grove, California • National City, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 9,159
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Akron, Ohio
- Conditions
- Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
- Interventions
- ASP0113, Placebo
- Biological · Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 22 more
- Conditions
- Stage III Pancreatic Cancer
- Interventions
- SOC, NanoKnife System
- Drug · Device
- Lead sponsor
- Angiodynamics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 14
- States / cities
- La Jolla, California • Gainesville, Florida • Miami, Florida + 10 more
- Conditions
- Perimenopause, Hypertension
- Interventions
- Terry Naturally® melatonin 5mg SR, Placebo
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 55 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Traumatic Brain Injury
- Interventions
- Counselor-assisted problem solving (CAPS), Internet-resource comparison (IRC)
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Rochester, Minnesota • Cincinnati, Ohio + 1 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- BIBW 2992
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more
- Conditions
- Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
- Conditions
- Hepatorenal Syndrome, Acute Kidney Injury
- Interventions
- R2R01, Terlipressin
- Drug
- Lead sponsor
- River 2 Renal Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Tolvaptan MR, Tolvaptan IR
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
- Conditions
- Breast Neoplasms
- Interventions
- Sham treatment, Healing Touch
- Behavioral
- Lead sponsor
- University of Wisconsin, Milwaukee
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Refractory Infantile Spasms
- Interventions
- JBPOS0101
- Drug
- Lead sponsor
- Bio-Pharm Solutions Co., Ltd.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1021
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more
- Conditions
- Stroke
- Interventions
- Augmented activity feedback, Speed-only feedback
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Worcester, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
- Conditions
- Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
- Radiation · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia
- Interventions
- PS-341
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • Houston, Texas
- Conditions
- Hypertension
- Interventions
- Rheos® Baroreflex Hypertension System
- Device
- Lead sponsor
- CVRx, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
- Conditions
- Neuroendocrine Tumors in Lung
- Interventions
- Lanreotide (Autogel formulation), Placebo, Best Supportive Care
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Squamous Cell Carcinoma of the Penis, Usual Type
- Interventions
- ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection
- Procedure · Drug · Radiation
- Lead sponsor
- Institute of Cancer Research, United Kingdom
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Ulcerative Colitis
- Interventions
- Visilizumab
- Drug
- Lead sponsor
- Facet Biotech
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more
- Conditions
- Glioblastoma
- Interventions
- VB-111 + bevacizumab, Bevacizumab
- Drug
- Lead sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Rogers, Arizona • Irvine, California + 40 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Months to 29 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- NMS-03597812
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Duarte, California • Aurora, Colorado • Newark, Delaware + 4 more